EUVIMEDEUVIMED entdecken
Crossref

Radiotheranostics and the Future of Cancer Therapy: Harnessing Combination Strategies and AI

Ayad H. Hasan, Mohammadreza Azimi, Tola Abdulsattar Faraj, Nazila Biglari, Nazanin Musapour, Sadaf safaei, Houman Torabian Basmen, Soran K. Najmaldin, Zahrah Mohammed Maghdid, Mostafa kashani, Vesal Firoozi

Advanced Pharmaceutical Bulletin · 01.07.2026

DOI: 10.34172/apb.47174 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Pharmaceutical Bulletin, online erschienen am 01.07.2026. Verfasst von Ayad H. Hasan und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiotheranostics, defined as the subset of theranostics wherein both diagnostic imaging and therapeutic functions are specifically enabled by radionuclides, represents a transformative advancement in precision oncology, integrating diagnostic imaging and targeted radionuclide therapy within a single molecular platform. Through coupling radionuclides with highly specific vectors such as antibodies, peptides, or small molecules, this approach enables selective delivery of radiation to tumor sites expressing biomarkers such as prostate-specific membrane antigen (PSMA) and human epidermal growth factor receptor 2 (HER2), thereby maximizing tumor cytotoxicity while sparing healthy tissue. Radiopharmaceuticals are engineered through meticulous radionuclide selection (e.g., Lutetium-177 (¹⁷⁷Lu) or Actinium-225 (²²⁵Ac)) as well as optimized carrier systems that influence biodistribution, targeting efficiency, and clearance kinetics. Imaging modalities such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) aid in patient selection, dosimetry, and real-time visualization of therapeutic efficacy. In clinical studies, radiopharmaceuticals have exhibited efficacy across multiple cancers, including prostate, neuroendocrine, breast, and ovarian malignancies. Beyond direct DNA damage, these agents can stimulate immunogenic cell death, boosting anti-tumor immunity. Combining radiopharmaceuticals with immunotherapy, chemotherapy, or PARP inhibitors may offer benefits over standard of care. Further, integration of Artificial Intelligence (AI) into radiotherapy (RT) workflows can potentially revolutionize treatment planning, contouring, adaptive dose management, and predictive modeling. Collectively, radiotheranostics exemplifies evolution of cancer management toward a highly personalized paradigm, combining molecular targeting, multimodal imaging, and AI-driven optimization. As ongoing research refines carrier systems, expands the repertoire of radionuclides, and enhances combinatorial strategies, radiotheranostics remains at the forefront of next-generation cancer therapeutics.

Zitieren

APA

Hasan, A. H., Azimi, M., Faraj, T. A., Biglari, N., Musapour, N., safaei, S., Basmen, H. T., Najmaldin, S. K., Maghdid, Z. M., kashani, M., & Firoozi, V. (2026). Radiotheranostics and the Future of Cancer Therapy: Harnessing Combination Strategies and AI. Advanced Pharmaceutical Bulletin. https://doi.org/10.34172/apb.47174

Vancouver

Hasan AH, Azimi M, Faraj TA, Biglari N, Musapour N, safaei S, et al. Radiotheranostics and the Future of Cancer Therapy: Harnessing Combination Strategies and AI. Advanced Pharmaceutical Bulletin. 2026. doi:10.34172/apb.47174

BibTeX
@article{Hasan2026,
  author = {Hasan, Ayad H. and Azimi, Mohammadreza and Faraj, Tola Abdulsattar and Biglari, Nazila and Musapour, Nazanin and safaei, Sadaf and Basmen, Houman Torabian and Najmaldin, Soran K. and Maghdid, Zahrah Mohammed and kashani, Mostafa and Firoozi, Vesal},
  title = {Radiotheranostics and the Future of Cancer Therapy: Harnessing Combination Strategies and AI},
  journal = {Advanced Pharmaceutical Bulletin},
  year = {2026},
  doi = {10.34172/apb.47174}
}
Kostenlos starten →